Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.31 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23696529 | 0.85 | HRH3 (0.41) | HRH3PIK3CDSMN1; SMN2KDM4ECYP2D6 | |
| SCHEMBL19124101 | 0.81 | SMN1; SMN2 (0.36) | HRH3SMN1; SMN2 | |
| SCHEMBL25071623 | 0.79 | HRH3 (0.42) | HRH3PIK3CDSMN1; SMN2KDM4ECYP2D6 | |
| SCHEMBL22309866 | 0.78 | HRH3 (0.41) | HRH3PIK3CDSMN1; SMN2KDM4ECYP2D6 | |
| SCHEMBL20653188 | 0.77 | CHRM4 (0.33) | — | |
| SCHEMBL22856539 | 0.76 | HRH3 (0.47) | HRH3PIK3CDSMN1; SMN2CYP2D6 | |
| SCHEMBL23945606 | 0.76 | HRH3 (0.40) | HRH3PIK3CDSMN1; SMN2KDM4ECYP2D6 | |
| SCHEMBL22856073 | 0.76 | SMN1; SMN2 (0.41) | HRH3PIK3CDSMN1; SMN2KDM4ECYP2D6 | |
| SCHEMBL23696290 | 0.75 | ALDH1A1 (0.41) | HRH3SMN1; SMN2KDM4E | |
| SCHEMBL21107430 | 0.74 | PIK3CD (0.43) | HRH3PIK3CDSMN1; SMN2KDM4ECYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190016689-A1 | NOVEL FLUORINATED QUINAZOLINE DERIVATIVES AS EGFR INHIBITORS | TRILLIUM THERAPEUTICS INC. (CA) | 2019-01-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190016689-A1 | NOVEL FLUORINATED QUINAZOLINE DERIVATIVES AS EGFR INHIBITORS | EGFR, ERBB2, ERBB4 | HRH3 2220/4885PIK3CD 342/4885SMN1; SMN2 4778/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.